1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Headaches

Fremanezumab for preventing migraine

Technology appraisal guidance [TA764] Published: 02 February 2022

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 167 KB 02 February 2022  

Final draft guidance

  • Final draft guidance  
  • Final appraisal document PDF 351 KB 16 December 2021  
  • Public committee slides PDF 598 KB 16 December 2021  
  • Committee papers PDF 663 KB 16 December 2021  

Final draft guidance: TA631

  • Final draft guidance: TA631  
  • Committee papers PDF 2.95 MB 12 March 2020  
  • Final appraisal document PDF 383 KB 12 March 2020  
  • Public committee slides PDF 1.03 MB 12 March 2020  

Draft guidance: TA631

  • Draft guidance: TA631  
  • Appraisal consultation document (PDF version) PDF 365 KB 15 November 2019  
  • Committee papers PDF 3.9 MB 15 November 2019  
  • Public committee slides PDF 839 KB 15 November 2019  

Invitation to participate

  • Final scope PDF 224 KB 24 October 2018  
  • Draft scope and provisional stakeholder list comments table (post-referral) PDF 601 KB 24 October 2018  
  • Final stakeholder list PDF 255 KB 24 October 2018  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: TA631

  • Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: TA631  
  • Draft scope post referral PDF 318 KB 04 April 2018  
  • Draft matrix post referral PDF 255 KB 04 April 2018